CYTOKINETICS INC — insider transactions
21 transactions on record · CYTK · CIK 1061983
Aggregates
computed from the filings belowPurchases, 12m
0
count of open-market buys
Sales, 12m
21
count of open-market sales
Buy / sell ratio, 12m
0.00
purchases per sale
Distinct insiders, 12m
3
Bought, 3m
$0
Sold, 3m
$4.9M
Median disclosure lag
0.0 d
trade date to filing date
Largest single trade, 24m
$1.1M
2026-07-30
Director share, 12m
42.9%
of transactions where role is stated
Current run
21 sells
consecutive same-direction transactions
Net 3m flow
-$4.9M
purchases minus sales
Total on record
21
Transactions
21 most recent shown| Disclosed | Traded | Lag, d | Insider | Role | Transaction | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-08 | 2026-09-08 | 0 | Malik Fady Ibraham | Development | Open market sale | 3,500 | $75.46 | $264.1K | filing |
| 2026-09-08 | 2026-09-08 | 0 | Malik Fady Ibraham | Development | Exercise of derivative | 3,500 | $7.80 | $27.3K | filing |
| 2026-09-08 | 2026-09-08 | 0 | Malik Fady Ibraham | Development | Exercise of derivative | 3,500 | $0.00 | — | filing |
| 2026-08-31 | 2026-08-31 | 0 | Blum Robert I | Director, CEO | Open market sale | 7,500 | $70.24 | $526.8K | filing |
| 2026-08-31 | 2026-08-31 | 0 | Blum Robert I | Director, CEO | Exercise of derivative | 7,500 | $10.60 | $79.5K | filing |
| 2026-08-31 | 2026-08-31 | 0 | Blum Robert I | Director, CEO | Exercise of derivative | 7,500 | $0.00 | — | filing |
| 2026-08-31 | 2026-08-31 | 0 | Callos Andrew | EVP, Chief Commercial Officer | Exercise of derivative | 10,000 | $0.00 | — | filing |
| 2026-08-31 | 2026-08-31 | 0 | Callos Andrew | EVP, Chief Commercial Officer | Exercise of derivative | 10,000 | $23.26 | $232.6K | filing |
| 2026-08-31 | 2026-08-31 | 0 | Callos Andrew | EVP, Chief Commercial Officer | Open market sale | 10,000 | $70.24 | $702.4K | filing |
| 2026-08-10 | 2026-08-10 | 0 | Blum Robert I | Director, CEO | Open market sale | 7,500 | $76.76 | $575.7K | filing |
| 2026-08-10 | 2026-08-10 | 0 | Blum Robert I | Director, CEO | Exercise of derivative | 7,500 | $0.00 | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Blum Robert I | Director, CEO | Exercise of derivative | 7,500 | $10.60 | $79.5K | filing |
| 2026-07-30 | 2026-07-30 | 0 | Callos Andrew | EVP, Chief Commercial Officer | Open market sale | 14,000 | $79.88 | $1.1M | filing |
| 2026-07-30 | 2026-07-30 | 0 | Callos Andrew | EVP, Chief Commercial Officer | Exercise of derivative | 14,000 | $23.26 | $325.6K | filing |
| 2026-07-30 | 2026-07-30 | 0 | Callos Andrew | EVP, Chief Commercial Officer | Exercise of derivative | 14,000 | $0.00 | — | filing |
| 2026-07-27 | 2026-07-27 | 0 | Blum Robert I | Director, President & CEO | Open market sale | 7,500 | $80.87 | $606.5K | filing |
| 2026-07-27 | 2026-07-27 | 0 | Blum Robert I | Director, President & CEO | Exercise of derivative | 7,500 | $10.60 | $79.5K | filing |
| 2026-07-27 | 2026-07-27 | 0 | Blum Robert I | Director, President & CEO | Exercise of derivative | 7,500 | $0.00 | — | filing |
| 2026-07-23 | 2026-07-21 | 2 | Malik Fady Ibraham | EVP Research & Development | Exercise of derivative | 3,500 | $0.00 | — | filing |
| 2026-07-23 | 2026-07-21 | 2 | Malik Fady Ibraham | EVP Research & Development | Open market sale | 3,500 | $80.59 | $282.1K | filing |
| 2026-07-23 | 2026-07-21 | 2 | Malik Fady Ibraham | EVP Research & Development | Exercise of derivative | 3,500 | $7.80 | $27.3K | filing |